+Compare
ARAV
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
10.09M

ARAV Aravive Forecast, Technical & Fundamental Analysis

a developer of therapies for solid tumors and hematologic malignancies

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ARAV with price predictions
07:00 PM EST Nov 27, 2023

ARAV saw its Stochastic Oscillator recovers from the overbought zone

The Stochastic Oscillator for ARAV moved out of overbought territory on November 27, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 50 similar instances where the indicator exited the overbought zone. In of the 50 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ARAV moved below its 50-day moving average on November 27, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARAV crossed bearishly below the 50-day moving average on November 03, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARAV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ARAV entered a downward trend on November 28, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 28, 2023. You may want to consider a long position or call options on ARAV as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARAV advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.928) is normal, around the industry mean (20.498). P/E Ratio (0.000) is within average values for comparable stocks, (137.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.811). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.713) is also within normal values, averaging (329.636).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARAV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARAV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 33%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -21% and the average quarterly volume growth was 24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

ARAV is expected to report earnings to rise 55.82% to -16 cents per share on March 29

Aravive ARAV Stock Earnings Reports
Q4'23
Est.
$-0.16
Q3'23
Missed
by $0.06
Q2'23
Missed
by $0.04
Q1'23
Missed
by $0.39
Q4'22
Missed
by $0.16
The last earnings report on November 28 showed earnings per share of -10 cents, missing the estimate of -3 cents. With 1.02M shares outstanding, the current market capitalization sits at 10.09M.
A.I. Advisor
published General Information

General Information

a developer of therapies for solid tumors and hematologic malignancies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3730 Kirby Drive
Phone
+1 936 355-1910
Employees
23
Web
https://www.aravive.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVCT8.250.40
+5.10%
Nuvectis Pharma
RNG29.051.27
+4.57%
RINGCENTRAL
FRZA0.630.02
+3.16%
Forza X1
MRO25.32N/A
N/A
Marathon Oil Corp
VMEO3.69-0.11
-2.89%
Vimeo

ARAV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAV has been loosely correlated with BPTH. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAV jumps, then BPTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAV
1D Price
Change %
ARAV100%
-4.52%
BPTH - ARAV
46%
Loosely correlated
+0.28%
RAPT - ARAV
31%
Poorly correlated
+3.11%
CCCC - ARAV
31%
Poorly correlated
+4.67%
VXRT - ARAV
31%
Poorly correlated
-3.57%
ATNM - ARAV
30%
Poorly correlated
-5.85%
More

Groups containing ARAV

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAV
1D Price
Change %
ARAV100%
-4.52%
biotechnology
(undefined stocks)
20%
Poorly correlated
+0.27%
cancer
(undefined stocks)
19%
Poorly correlated
-0.43%
stem cells
(undefined stocks)
19%
Poorly correlated
+0.93%
plastic surgery
(undefined stocks)
19%
Poorly correlated
+1.84%
drugs
(undefined stocks)
18%
Poorly correlated
+0.28%